Corbus Pharmaceuticals Holdings, Inc.(NASDAQ : CRBP)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.74%||176.97||0.7%||$1352.49m|
|BMY||Bristol-Myers Squibb Co.||0.36%||76.23||1.0%||$1197.90m|
|MRK||Merck & Co., Inc.||1.26%||93.25||0.7%||$1136.00m|
|LLY||Eli Lilly & Co.||4.49%||299.11||1.1%||$892.99m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.65%||141.96||0.0%||$458.27m|
|HZNP||Horizon Therapeutics Plc||1.13%||90.35||5.4%||$200.40m|
|NVO||Novo Nordisk A/S||3.49%||107.68||0.1%||$190.60m|
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.